Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Compugen Ltd (CGEN)

Compugen Ltd (CGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Compugen: Q2 Earnings Snapshot AP - Mon Aug 3, 6:03AM CDT

Compugen: Q2 Earnings Snapshot

CGEN : 2.44 (+2.52%)
Compugen Reports Second Quarter 2026 Results PR Newswire - Mon Aug 3, 6:00AM CDT

COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027

CGEN : 2.44 (+2.52%)
Compugen to Participate in BTIG Biotechnology Conference 2026 PR Newswire - Tue Jul 21, 6:00AM CDT

HOLON, Israel , July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...

CGEN : 2.44 (+2.52%)
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 PR Newswire - Mon Jul 20, 6:00AM CDT

HOLON, Israel , July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered...

CGEN : 2.44 (+2.52%)
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress PR Newswire - Thu Jun 18, 6:00AM CDT

HOLON, Israel , June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered...

CGEN : 2.44 (+2.52%)
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 PR Newswire - Thu Jun 11, 6:00AM CDT

HOLON, Israel , June 11, 2026 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery...

CGEN : 2.44 (+2.52%)
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development PR Newswire - Mon Jun 8, 6:00AM CDT

HOLON, Israel , June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...

CGEN : 2.44 (+2.52%)
MarketBeat.com
Compugen Q1 Earnings Call Highlights MarketBeat - Mon May 18, 9:08AM CDT

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company...

CGEN : 2.44 (+2.52%)
Compugen: Q1 Earnings Snapshot AP - Mon May 18, 6:58AM CDT

Compugen: Q1 Earnings Snapshot

CGEN : 2.44 (+2.52%)
Compugen Reports First Quarter 2026 Results PR Newswire - Mon May 18, 6:00AM CDT

HOLON, Israel , May 18, 2026 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered...

CGEN : 2.44 (+2.52%)

Barchart Exclusives

This High-Yield Exchange Stock Just Raised Its Dividend by Nearly 20% Barchart - Wed Aug 19, 6:30PM CDT
Cboe Global Markets raised its quarterly dividend by 19% to $0.86 per share on Aug. 13, marking the 16th consecutive year of increases, supported by strong options trading volumes and solid second-quarter results. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.